Formoterol in the treatment of experimental cancer cachexia: effects on heart function

Journal of Cachexia, Sarcopenia and Muscle

Volumn 5, Issue 4, 2014, Pages 315-320

  Toledo, Míriam ^a   Springer, Jochen ^b   Busquets, Sílvia ^a   Tschirner, Anika ^b   López Soriano, Francisco J ^a   Anker, Stefan D ^b   Argilés, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cachexia; Cancer; Formoterol; Heart function; Muscle wasting

Indexed keywords

FORMOTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; BODY WATER; CACHEXIA; CONTROLLED STUDY; DIAPHRAGM MUSCLE; EXPERIMENTAL NEOPLASM; GASTROCNEMIUS MUSCLE; HEART CONTRACTION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART STROKE VOLUME; HEART VENTRICLE SIZE; HEART WEIGHT; LEAN BODY WEIGHT; MALE; MUSCLE MASS; NONHUMAN; RAT; SOLEUS MUSCLE; YOSHIDA SARCOMA;

EID: 84951558439     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-014-0153-y     Document Type: Article

References (39)

1. Warren S. The immediate cause of death in cancer. Am J Med Sci. 1932;184:610–3.
2. Argilés JM, Moore-Carrasco R, Fuster G, Busquets S, López-Soriano FJ. Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol. 2003;35:405–9.
3. Argiles JM, Alvarez B, Lopez-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev. 1997;17:477–98.
4. Xu H, Crawford D, Hutchinson KR, Youtz DJ, Lucchesi PA, Velten M, et al. Myocardial dysfunction in an animal model of cancer cachexia. Life Sci. 2011;88:406–10.
5. Olivan M, Springer J, Busquets S, Tschirner A, Figueras M, Toledo M, et al. Theophylline is able to partially revert cachexia in tumour-bearing rats. Nutr Metab. 2012;9:76.
6. Der-Torossian H, Gourin CG, Couch ME. Translational implications of novel findings in cancer cachexia: the use of metabolomics and the potential of cardiac malfunction. Curr Opin Support Palliat Care. 2012;6:446–50.
7. Tian M, Nishijima Y, Asp ML, Stout MB, Reiser PJ, Belury MA. Cardiac alterations in cancer-induced cachexia in mice. Int J Oncol. 2010;37:347–53.
8. Mühlfeld C, Das SK, Heinzel FR, Schmidt A, Post H, Schauer S, et al. Cancer induces cardiomyocyte remodeling and hypoinnervation in the left ventricle of the mouse heart. PLoS One. 2011;6:e20424.
9. Schünemann M, Anker SD, Rauchhaus M. Cancer fatigue syndrome reflects clinically non-overt heart failure: an approach towards onco-cardiology. Nat Clin Pr. Oncol. 2008;5:632–3.
10. Tian M, Asp ML, Nishijima Y, Belury MA. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int J Oncol. 2011;39:1321–6.
11. Cosper PF, Leinwand LA. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res. 2011;71:1710–20.
12. Wysong A, Couch M, Shadfar S, Li L, Rodriguez JE, Asher S, et al. NF-κB inhibition protects against tumor-induced cardiac atrophy in vivo. Am J Pathol. 2011;178:1059–68.
13. Drott C, Lundholm K. Glucose uptake and amino acid metabolism in perfused hearts from tumor-bearing rats. J Surg Res. 1990;49:62–8.
14. Hyltander A, Drott C, Körner U, Sandström R, Lundholm K. Elevated energy expenditure in cancer patients with solid tumours. Eur J Cancer. 1991;27:9–15.
15. Argilés JM, Anguera A, Stemmler B. A new look at an old drug for the treatment of cancer cachexia: megestrol acetate. Clin. Nutr. 2013;32:319–24.
16. Argilés JM, López-Soriano FJ, Busquets S. Novel approaches to the treatment of cachexia. Drug Discov Today. 2008;13:73–8.
17. Agbenyega ET, Wareham AC. Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone. Comp Biochem Physiol Comp Physiol. 1992;102:141–5.
18. Rajab P, Fox J, Riaz S, Tomlinson D, Ball D, Greenhaff PL. Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. Am J Physiol Regul Integr Comp Physiol. 2000;279:R1076–81.
19. Hinkle RT, Hodge KMB, Cody DB, Sheldon RJ, Kobilka BK, Isfort RJ. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve. 2002;25:729–34.
20. Wineski LE, von Deutsch DA, Abukhalaf IK, Pitts SA, Potter DE, Paulsen DF. Muscle-specific effects of hindlimb suspension and clenbuterol in mature male rats. Cells Tissues Organs. 2002;171:188–98.
21. Yang YT, McElligott MA. Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J. 1989;261:1–10.
22. Mersmann HJ. Overview of the effects of beta-adrenergic receptor agonists on animal growth including mechanisms of action. J Anim Sci. 1998;76:160–72.
23. Burniston JG, Ng Y, Clark WA, Colyer J, Tan L-B, Goldspink DF. Myotoxic effects of clenbuterol in the rat heart and soleus muscle. J Appl Physiol. 2002;93:1824–32.
24. Libretto SE. A review of the toxicology of salbutamol (albuterol). Arch Toxicol. 1994;68:213–6.
25. Pack RJ, Alley MR, Dallimore JA, Lapwood KR, Burgess C, Crane J. The myocardial effects of fenoterol, isoprenaline and salbutamol in normoxic and hypoxic sheep. Int J Exp Pathol. 1994;75:357–62.
26. Busquets S, Figueras MT, Fuster G, Almendro V, Moore-Carrasco R, Ametller E, et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res. 2004;64:6725–31.
27. Greig CA, Johns N, Gray C, Macdonald A, Stephens NA, Skipworth RJE, et al. Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy. Support Care Cancer. 2014;22:1269–75.
28. Tessitore L, Costelli P, Bonetti G, Baccino FM. Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch Biochem Biophys. 1993/10/01 ed. Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, Italy.; 1993;306:52–8.
29. Akashi YJ, Palus S, Datta R, Halem H, Taylor JE, Thoene-Reineke C, et al. No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. Int J Cardiol. 2009;137:267–75.
30. Ametller E, Busquets S, Fuster G, Figueras MT, Olivan M, de Oliveira CCF, et al. Formoterol may activate rat muscle regeneration during cancer cachexia. Insciences J. 2011;1:1–17.
31. Montalbano AM, Anzalone G, Albano GD, Di Sano C, Gagliardo R, Bonanno A, et al. Beclomethasone dipropionate and formoterol reduce oxidative/nitrosative stress generated by cigarette smoke extracts and IL-17A in human bronchial epithelial cells. Eur J Pharmacol. 2013;718:418–27.
32. Houten L, Reilley AA. An investigation of the cause of death from cancer. J Surg Oncol. 1980;13:111–6.
33. McBride W, Jackman JD, Gammon RS, Willerson JT. High-output cardiac failure in patients with multiple myeloma. N Engl J Med. 1988;319:1651–3.
34. Springer J, Tschirner A, Hartman K, von Haehling S, Anker SD, Doehner W. The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy. Int J Cardiol. 2013;168:3527–31.
35. Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur. Heart J. 2013.
36. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 1999;100:2210–2.
37. Shizukuda Y, Buttrick PM. Subtype specific roles of beta-adrenergic receptors in apoptosis of adult rat ventricular myocytes. J Mol Cell Cardiol. 2002;34:823–31.
38. De Mey C, Nassr N, Lahu G. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study. BMC Clin Pharmacol. 2011;11:7.
39. Watson DC, Sargianou M, Leivaditis V, Anagnostopoulos C. Beta2-adrenergic activation via administration of atenolol/formoterol combination increases contractility and coronary blood flow in isolated rat hearts. Hell J Cardiol. 2013;54:341–7.